Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Discovery and preclinical evaluation of SH-379 as a novel anti-LOH agent

Aug. 22, 2019

Initiator Pharma provides an update on IPED-2015 and IP-2018 development

Aug. 16, 2019

SHR-1653 as a novel highly potent and selective OTR antagonist

Aug. 14, 2019

Eloxx Pharmaceuticals initiates phase II study for ELX-02 in cystinosis

Aug. 6, 2019

Aronora opens phase II study of AB-002 in end-stage renal disease patients on chronic hemodialysis

Aug. 1, 2019

Roystonea regia lipid extract reduces lower urinary tract symptoms in men with BPH

July 26, 2019

Regulus outlines FDA requirements to reinitiate MAD studies with RGLS-4326

July 24, 2019

BioMarin Pharmaceutical identifies hydroxyacid oxidase 1 inhibitors

July 24, 2019

DiaMedica reports phase Ib interim data on DM-199 in chronic kidney disease

June 20, 2019

Arch Biopartners initiates phase I study of Metablok

June 20, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...